Breaking News

Financial Report: Lilly

April 24, 2014

Cymbalta and Evista patent expirations impact results


1Q Revenues: $4.7 billion (-16%)

1Q Earnings: $749.9 million (-52%)

Comments: Results were impacted by U.S. patent expirations for Cymbalta (-64% to $478.2 million) and Evista (-38% to $150.1 million). Humalog sales were up 3% to $632.7 million. Alimta sales were up 2% to $632.0 million. Cialis sales were $532.4 million, up 3%. R&D expenses were down 18% to $1.1 billion. In the quarter, the company gained approval for Cyramza for advanced or metastatic gastric cancer, and entered an agreement to acquire Novartis Animal Health for approximately $5.4 billion in cash.

blog comments powered by Disqus